Synlogic, Inc. stock is down -41.77% since 30 days ago. The next earnings date is Mar 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 22.22% of the previous 8 March’s closed higher than February. 0% of analysts rate it a buy.
Synlogic, Inc. engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria and homocystinuria. The company is also developing SYNB1891 that is in Phase I clinical trial to treat solid tumors and lymphoma.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!